All In Biotech

Drug Trial Radar · NCT02028780

Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 (Idarucizumab) Administered Alone or With Dabigatran Etexilate in Japanese Healthy Subjects

Randomised, Double-blind Within Dose Groups, Placebo-controlled Phase I Trial in Healthy Japanese Male Volunteers to Investigate Safety, Tolerability and Pharmacokinetics of Different Doses of BI 655075 (Part 1) and to Explore the Effective Dose of BI 655075 to Reverse Dabigatran Anticoagulant Activity (Part 2).

Last checked: Nov 20, 2026Latest source record: Feb 11, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

80

Actual

Start

Jan 2014

Primary completion

Aug 2014

Study completion Aug 2014

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Jan 7, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
Male only, from 20 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective is to investigate the safety, tolerability and pharmacokinetics of BI 655075 following intravenous administration of single rising doses of BI 655075 when administered alone and after administration of dabigatran.

Conditions

  • Healthy

Interventions

  • Placebo to doseDrug

    placebo

  • IdarucizumabDrug

    short infusion

  • Placebo to IdarucizumabDrug

    Placebo to Idarucizumab

  • dabigatranDrug

    2 capsules dabigatran

  • IdarucizumabDrug

    short infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects With Drug-related Adverse Events in Part 1 and Part 2Time frame: From first drug administration until 13 weeks after the last drug administration, upto 98 days (Part-I) & upto 108 days (Part-II)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • 1321.5.00001 Boehringer Ingelheim Investigational Site

    Sumida-ku, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.